BiotechTube

linaclotide + placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Constipation-predominant Irritable Bowel Syndrome (IBS-C)

Conditions

Constipation-predominant Irritable Bowel Syndrome (IBS-C)

Trial Timeline

Aug 10, 2012 → Dec 7, 2013

NCT ID
NCT01714843

About linaclotide + placebo

linaclotide + placebo is a phase 2 stage product being developed by Astellas Pharma for Constipation-predominant Irritable Bowel Syndrome (IBS-C). The current trial status is completed. This product is registered under clinical trial identifier NCT01714843. Target conditions include Constipation-predominant Irritable Bowel Syndrome (IBS-C).

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT02809105Phase 3Completed
NCT02316899Phase 3Completed
NCT01714843Phase 2Completed

Competing Products

1 competing product in Constipation-predominant Irritable Bowel Syndrome (IBS-C)

See all competitors
ProductCompanyStageHype Score
Neomycin + Placebo + RifaximinBausch HealthPre-clinical
18

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85